Sarepta’s blockbuster gene therapy has come under scrutiny following a string of patient deaths.

Investing.com -- Traws Pharma Inc (NASDAQ:TRAW) stock surged 14.5% Monday after the clinical-stage biopharmaceutical company announced the completion of enrollment in its Phase 2 study of ratutrelvir, ...

CoreWeave Inc (NASDAQ: CRWV) gained 9.5% to $101.88 after the company announced an expanded collaboration with Nvidia ...

Over the years we’ve shared numerous investment ideas on Livewire. But that alone ignores the other critical piece to good ...

Alcon's (VTX:ALC) stock is up by 6.3% over the past three months. We wonder if and what role the company's financials play in ...

Actinogen Medical soon should find out whether its pivotal Xanamia Alzheimer's trial is futile, or hitting the right notes. .

Google is quietly launching on demand practice exams for standardized tests in Gemini, starting with the SAT. Several stocks ...

Go ahead, drop your kids off at grandma and grandpa’s house. Sure, that special bonding time is fun, but a new study has ...

Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of ...

Sarepta shares jump 5% after hours as company sets January 26 for 3-year Elevidys data following FDA safety warning and label restrictions.

Willdan's architect-to-builder model secures recurring, high-margin revenue, with organic net revenue growth at 20% Y/Y. See ...